|
Gene: GLB1 |
Gene summary for GLB1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GLB1 | Gene ID | 2720 |
Gene name | galactosidase beta 1 | |
Gene Alias | EBP | |
Cytomap | 3p22.3 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | P16278 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2720 | GLB1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.49e-09 | 4.47e-01 | -0.1954 |
2720 | GLB1 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.70e-02 | 3.09e-01 | -0.1464 |
2720 | GLB1 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.41e-07 | 5.12e-01 | 0.096 |
2720 | GLB1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.32e-03 | 3.74e-01 | 0.294 |
2720 | GLB1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.33e-19 | 7.58e-01 | 0.3859 |
2720 | GLB1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.70e-05 | 3.48e-01 | 0.3005 |
2720 | GLB1 | A015-C-203 | Human | Colorectum | FAP | 2.81e-04 | -1.23e-01 | -0.1294 |
2720 | GLB1 | A002-C-201 | Human | Colorectum | FAP | 2.43e-02 | -1.42e-01 | 0.0324 |
2720 | GLB1 | A002-C-205 | Human | Colorectum | FAP | 1.03e-03 | -7.54e-02 | -0.1236 |
2720 | GLB1 | A015-C-006 | Human | Colorectum | FAP | 1.16e-02 | -1.01e-01 | -0.0994 |
2720 | GLB1 | A015-C-106 | Human | Colorectum | FAP | 1.03e-02 | -9.05e-02 | -0.0511 |
2720 | GLB1 | A002-C-114 | Human | Colorectum | FAP | 3.59e-03 | -1.13e-01 | -0.1561 |
2720 | GLB1 | A015-C-104 | Human | Colorectum | FAP | 1.34e-04 | -1.70e-01 | -0.1899 |
2720 | GLB1 | A002-C-016 | Human | Colorectum | FAP | 5.74e-05 | -1.45e-01 | 0.0521 |
2720 | GLB1 | A015-C-002 | Human | Colorectum | FAP | 1.82e-02 | -2.20e-01 | -0.0763 |
2720 | GLB1 | A002-C-116 | Human | Colorectum | FAP | 1.21e-05 | -1.27e-01 | -0.0452 |
2720 | GLB1 | A014-C-008 | Human | Colorectum | FAP | 1.26e-02 | -1.80e-01 | -0.191 |
2720 | GLB1 | A018-E-020 | Human | Colorectum | FAP | 3.65e-03 | -8.61e-02 | -0.2034 |
2720 | GLB1 | CRC-3-11773 | Human | Colorectum | CRC | 1.52e-02 | -6.37e-02 | 0.2564 |
2720 | GLB1 | LZE4T | Human | Esophagus | ESCC | 4.67e-04 | 2.13e-01 | 0.0811 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00162417 | Oral cavity | OSCC | regulation of macroautophagy | 96/7305 | 141/18723 | 2.33e-12 | 9.75e-11 | 96 |
GO:007149620 | Oral cavity | OSCC | cellular response to external stimulus | 186/7305 | 320/18723 | 2.56e-12 | 1.05e-10 | 186 |
GO:00070335 | Oral cavity | OSCC | vacuole organization | 115/7305 | 180/18723 | 1.11e-11 | 4.00e-10 | 115 |
GO:000662618 | Oral cavity | OSCC | protein targeting to mitochondrion | 72/7305 | 100/18723 | 2.10e-11 | 7.18e-10 | 72 |
GO:004854520 | Oral cavity | OSCC | response to steroid hormone | 186/7305 | 339/18723 | 1.86e-09 | 4.42e-08 | 186 |
GO:003166819 | Oral cavity | OSCC | cellular response to extracellular stimulus | 141/7305 | 246/18723 | 3.99e-09 | 8.95e-08 | 141 |
GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
GO:190165419 | Oral cavity | OSCC | response to ketone | 114/7305 | 194/18723 | 1.82e-08 | 3.60e-07 | 114 |
GO:19021155 | Oral cavity | OSCC | regulation of organelle assembly | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
GO:00105087 | Oral cavity | OSCC | positive regulation of autophagy | 77/7305 | 124/18723 | 1.59e-07 | 2.61e-06 | 77 |
GO:003166918 | Oral cavity | OSCC | cellular response to nutrient levels | 121/7305 | 215/18723 | 1.96e-07 | 3.17e-06 | 121 |
GO:004259416 | Oral cavity | OSCC | response to starvation | 111/7305 | 197/18723 | 5.68e-07 | 8.19e-06 | 111 |
GO:000926717 | Oral cavity | OSCC | cellular response to starvation | 91/7305 | 156/18723 | 7.55e-07 | 1.06e-05 | 91 |
GO:000091010 | Oral cavity | OSCC | cytokinesis | 97/7305 | 173/18723 | 3.82e-06 | 4.51e-05 | 97 |
GO:00066432 | Oral cavity | OSCC | membrane lipid metabolic process | 111/7305 | 203/18723 | 4.02e-06 | 4.69e-05 | 111 |
GO:19050374 | Oral cavity | OSCC | autophagosome organization | 63/7305 | 103/18723 | 4.30e-06 | 4.98e-05 | 63 |
GO:19037478 | Oral cavity | OSCC | regulation of establishment of protein localization to mitochondrion | 35/7305 | 50/18723 | 8.76e-06 | 9.31e-05 | 35 |
GO:00726658 | Oral cavity | OSCC | protein localization to vacuole | 44/7305 | 67/18723 | 8.92e-06 | 9.44e-05 | 44 |
GO:19035337 | Oral cavity | OSCC | regulation of protein targeting | 51/7305 | 81/18723 | 1.08e-05 | 1.13e-04 | 51 |
GO:00000454 | Oral cavity | OSCC | autophagosome assembly | 60/7305 | 99/18723 | 1.09e-05 | 1.14e-04 | 60 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00052 | Colorectum | FAP | Galactose metabolism | 12/1404 | 32/8465 | 3.61e-03 | 1.53e-02 | 9.29e-03 | 12 |
hsa000521 | Colorectum | FAP | Galactose metabolism | 12/1404 | 32/8465 | 3.61e-03 | 1.53e-02 | 9.29e-03 | 12 |
hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa006003 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa0060012 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa041424 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
hsa0414211 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa00511 | Liver | HCC | Other glycan degradation | 15/4020 | 18/8465 | 1.96e-03 | 6.91e-03 | 3.84e-03 | 15 |
hsa00600 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa005111 | Liver | HCC | Other glycan degradation | 15/4020 | 18/8465 | 1.96e-03 | 6.91e-03 | 3.84e-03 | 15 |
hsa006001 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa041425 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa006002 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
hsa0414212 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0060011 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLB1 | SNV | Missense_Mutation | c.1336N>C | p.Ala446Pro | p.A446P | P16278 | protein_coding | tolerated(0.2) | possibly_damaging(0.897) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
GLB1 | SNV | Missense_Mutation | novel | c.302N>G | p.Asp101Gly | p.D101G | P16278 | protein_coding | tolerated(0.07) | possibly_damaging(0.863) | TCGA-E9-A245-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
GLB1 | SNV | Missense_Mutation | c.1628N>T | p.Ser543Leu | p.S543L | P16278 | protein_coding | tolerated(0.14) | possibly_damaging(0.543) | TCGA-GM-A2DF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
GLB1 | SNV | Missense_Mutation | c.592N>C | p.Asp198His | p.D198H | P16278 | protein_coding | deleterious(0.05) | possibly_damaging(0.9) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
GLB1 | insertion | Frame_Shift_Ins | novel | c.1526_1527insCG | p.Trp509CysfsTer92 | p.W509Cfs*92 | P16278 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
GLB1 | insertion | Frame_Shift_Ins | novel | c.1524_1525insATGGGGGAAAGGGAATCTTCCCACAT | p.Trp509MetfsTer100 | p.W509Mfs*100 | P16278 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
GLB1 | insertion | Frame_Shift_Ins | novel | c.1909_1910insGTGTACATAGTATGGTATATCT | p.Thr637SerfsTer29 | p.T637Sfs*29 | P16278 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
GLB1 | deletion | Frame_Shift_Del | novel | c.237delN | p.Ile80SerfsTer41 | p.I80Sfs*41 | P16278 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
GLB1 | SNV | Missense_Mutation | novel | c.790N>A | p.Leu264Met | p.L264M | P16278 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GLB1 | SNV | Missense_Mutation | c.423N>T | p.Glu141Asp | p.E141D | P16278 | protein_coding | tolerated(0.18) | benign(0.006) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |